FORSYTH DOUGLAS

SEC Form 4 insider trading activity

FORSYTH DOUGLAS has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.

On the most recent filing, FORSYTH DOUGLAS is listed as Director at Inhibrx Biosciences, Inc. Inside the rolling window, FORSYTH DOUGLAS reported 1 open-market purchase totaling $287K in INBX and no open-market sales.

Companies traded

Other insiders at INBX

Insider Buying

$287K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
INBX
FORSYTH DOUGLAS
Purchase$287KSep 8SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has FORSYTH DOUGLAS made?

FORSYTH DOUGLAS has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does FORSYTH DOUGLAS trade?

FORSYTH DOUGLAS has filed SEC Form 4 disclosures for 1 company, including INBX.

When was FORSYTH DOUGLAS's most recent SEC Form 4 filing?

FORSYTH DOUGLAS's most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.

What is FORSYTH DOUGLAS's total buy and sell value in the current window?

Inside the rolling retention window, FORSYTH DOUGLAS bought $287K and sold $0 based on SEC Form 4 filings.

What was FORSYTH DOUGLAS's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 2,500 INBX shares on 2026-09-08, worth $287K, per SEC Form 4 filings.